Drug Shortage Report for RANITIDINE INJECTION USP

Last updated on 2023-11-17 History
Report ID 119246
Drug Identification Number 02256711
Brand name RANITIDINE INJECTION USP
Common or Proper name RANITIDINE
Company Name SANDOZ CANADA INCORPORATED
Market Status CANCELLED POST MARKET
Active Ingredient(s) RANITIDINE
Strength(s) 50MG
Dosage form(s) SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 50ML
ATC code A02BA
ATC description DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Reason for shortage Requirements related to complying with good manufacturing practices.
Anticipated start date 2020-09-14
Actual start date
Estimated end date Unknown
Actual end date 2021-03-01
Shortage status Resolved
Updated date 2023-11-17
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 110 RUE DE LAUZON
BOUCHERVILLE, QUEBEC
CANADA J4B 1E6
Company contact information 1 800-361-3062

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v9 2023-11-17 French Compare
v8 2023-11-17 English Compare
v7 2020-09-15 French Compare
v6 2020-09-15 English Compare
v5 2020-09-15 French Compare
v4 2020-09-15 English Compare
v3 2020-09-15 English Compare
v2 2020-06-30 French Compare
v1 2020-06-30 English Compare

Showing 1 to 9 of 9